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Background: This retrospective, multicenter study evaluated the feasibility and safety of 
high-dose rate electronic brachytherapy (EBT) as a postsurgical adjuvant radiation therapy for 
endometrial cancer.
Methods: Medical records were reviewed from 41 patients (age 40–89 years) with endometrial 
cancer (Federation of International Gynecology and Obstetrics stages IA–IIIC) treated at nine 
centers between April 2008 and October 2009. Treatment included intracavitary vaginal EBT 
alone (n = l6) at doses of 18.0–24.0 Gy in 3–4 fractions and EBT in combination with external 
beam radiation therapy (EBRT, n = 25) at a total radiation dose range of 40.0–80.4 Gy. Doses 
were prescribed to a depth of 5 mm from the applicator surface and to the upper third (n = 15) 
and the upper half (n = 26) of the vagina.
Results: Median follow-up was 3.8 (range 0.5–12.0) months. All 41 patients received the 
intended dose of radiation as prescribed. Adverse events occurred in 13 of 41 patients and were 
mild to moderate (Grade 1–2), consisting primarily of vaginal mucositis, rectal mucosal irrita-
tion and discomfort, and temporary dysuria and diarrhea. There were no Grade 3 adverse events 
in the EBT-only treatment group. One patient, who was being treated with the combination of 
EBT and EBRT for recurrent endometrial cancer, had a Grade 3 adverse event. No recurrences 
have been reported to date.
Conclusion: Electronic brachytherapy provides a feasible treatment option for postoperative 
adjuvant vaginal brachytherapy as sole radiation therapy and in combination with EBRT for 
primary endometrial cancer. Early and late toxicities were mild to moderate.
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Introduction
Endometrial cancer is the most common gynecologic cancer and the fourth most com-
mon type of cancer in women in the Western world.1 An estimated 42,160 women 
were diagnosed with endometrial cancer in 2009 in the US,1 with a majority of cases 
having early-stage disease.2 Early-stage endometrial cancer has a good prognosis, and 
five-year survival rates have recently increased to 80–90% in women who were treated 
with total abdominal hysterectomy, bilateral salpingo-oophorectomy (TAH-BSO), 
and adjuvant radiation therapy for Stage I disease. In a survey of over 21,000 patients 
with Stage I endometrial cancer, adjuvant radiation therapy was found to be   significantly 
  associated with improved survival.3 However, external beam radiation therapy (EBRT) 
in early-stage endometrial cancer has become less common due to the time and OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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  morbidity   associated with this form of low-dose rate radiation. 
High-dose rate (HDR) intracavitary brachytherapy, which 
provides dose rates greater than 100 centigray per hour, can 
be completed in a shorter time on an outpatient basis, with 
decreased radiation exposure to nontarget organs and tissue. 
With the increased trend to stage endometrial cancer patients 
surgically, vaginal brachytherapy as sole radiation therapy 
or combined with other modalities has become an essential 
part of adjuvant treatment for endometrial cancer. Numerous 
studies of the use of vaginal brachytherapy have demonstrated 
good control rates with minimal morbidity.4–13
HDR vaginal brachytherapy has typically relied on an 
192iridium source. However, this form of radiation requires an 
HDR afterloader unit and a shielded radiation vault, which is 
not financially feasible in smaller institutions or clinics and 
can present scheduling challenges at higher-volume centers. 
Electronic brachytherapy (EBT) utilizes a   miniaturized 
50 kilovoltage (kV) X-ray source that does not require a vault 
or an HDR afterloader unit. Minimal shielding, in the form 
of a rolling shield for staff and a half-apron over the lower 
abdomen of the patient, allows the therapist to be present 
in the treatment room, which significantly increases patient 
comfort. The device, once state registration, health physics, 
and regulatory requirements are met, can be moved from one 
procedure room to the next. EBT does not require storage 
and handling of isotopes.14,15
The Axxent® EBT system (Xoft, Inc, Sunnyvale, CA) 
has been utilized in the US for the treatment of breast cancer 
since 2005.15 In 2008, the US Food and Drug Administration 
provided clearance for the use of this EBT system with spe-
cifically designed applicators for the treatment of endometrial 
cancer. The objective of this retrospective multicenter study 
was to assess treatment feasibility and acute adverse events 
as documented in the records of patients treated with EBT 
as an adjuvant therapy for endometrial cancer.
Methods
Medical records were reviewed from 41 patients at nine 
institutions (Beverly Oncology and Imaging Center, Monte-
bello, CA; Swedish Covenant Medical Center, Chicago, IL; 
Rhode Island Hospital, Providence, RI; Signature Healthcare 
Brockton Hospital, Brockton, MA; AtlantiCare Regional 
Medical Center, Egg Harbor Township, NJ; St Francis 
Medical Center, Tulsa, OK; Southwest Oncology Centers, 
Scottsdale, AZ; Aspirus Regional Medical Center, Wausau, 
WI; and Exeter Hospital, Exeter, NH. The protocol was 
approved by the institutional review boards at the nine 
  participating centers.
Patients
The medical records were reviewed for 41 patients with 
  endometrial cancer who were treated with vaginal EBT 
between April 2008 and October 2009; follow-up visits 
took place between November 2008 and December 2009. 
Records of patients treated with EBT alone or EBT in com-
bination with EBRT were included. Records of patients 
currently enrolled in any other EBT study were excluded. 
No other exclusion criteria were established. The staging of 
endometrial cancer for each patient was done according to 
the Federation of International Gynecology and Obstetrics 
(FIGO) staging criteria (1988). The histopathologic grade 
was defined as G1 (well differentiated), G2 (moderately 
differentiated), and G3 (poorly differentiated).
Data collection
The data were collected retrospectively, with the centers 
sequentially numbered, and with patients sequentially 
numbered using three-digit numbers within each center. 
Adverse events were collected using Common Terminol-
ogy Criteria for Adverse Events version 3.0. Adverse events 
were rated based on the Common Terminology Criteria for 
Adverse Events version 3, and included grades 1 = mild, 
2 =   moderate, 3 = severe/undesirable, 4 = life-threatening/
disabling, 5 = death related to adverse event.
Materials
Vaginal EBT was delivered using the Axxent EBT system. The 
EBT system consists of the X-ray source, the vaginal cylinder 
applicator, and the controller. The X-ray source comprises a 
miniaturized 50 kV X-ray tube in a multilumen catheter that 
allows cooling fluid to circulate over the tube. The vaginal 
cylinder applicators were designed to provide transmission 
characteristics specifically for the low energy X-rays emitted 
by the electronic X-ray source. The cylinders are composed 
of common medical-grade polymers, and have a 94% ± 5% 
X-ray transmission with respect to water. The X-ray tube is 
approximately 2.25 mm in diameter and 15 mm long, attached 
to a high-voltage cable, and encapsulated within an electrical 
ground. The controller provides power to the X-ray source and 
allows the X-ray source to be translated within the applicator. 
The translation or pullback movement of the X-ray source 
within the applicator is designed to provide a desired dose of 
radiation in the tissue surrounding the cylinder.
Treatment
The prescription dose and brachytherapy treatment plans 
were prepared individually for each patient, typically based OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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on CT scans. BrachyVision™ treatment planning   software 
(Varian Medical Systems, Palo Alto, CA) or Plato™ treatment 
planning software (Nucletron, Columbia, MD) were used at 
most centers. A vaginal cylinder applicator was selected for 
each patient from the four sizes available (20 mm, 25 mm, 
30 mm, 35 mm). The applicator was inserted just prior to 
treatment and removed following treatment on each treat-
ment visit. Follow-up visits occurred periodically based on 
the standard practice at each study site.
statistics
Case report forms were submitted to a data coordinating 
center where data were entered into a Access® (Microsoft, 
Redmond, WA) database by an independent data manager. 
Analysis of the data was performed using SAS statistical 
analysis software (Version 9.1.3; Sas Institute, Cary, NC). The 
number of observations (n) and proportion are reported for 
both the treatment success and acute outcome endpoints.
Results
Patients
Records from 41 female patients were reviewed, most of 
whom (93%) were aged 50 years or older, with 31% being 
aged 70 years or older. Patient characteristics are listed in 
Table 1. A majority (68%) had early-stage endometrial cancer 
(stages IA–IIA) according to the FIGO gynecologic staging 
system (1988). The remaining patients had cancer stages 
IIB–IIIC, including one patient with recurrent cancer. The 
median follow-up was 3.8 (range 0.5–12.0) months.
Treatment
Patients with primary endometrial cancer (n = 40) and 
  recurrent endometrial cancer (n = 1) were treated with 
vaginal EBT alone (n = 16) or EBT in combination with 
EBRT (n = 25). All 41 patients received the intended dose 
of radiation as prescribed. When EBT was used alone, the 
mean prescription dose was 21.3 Gy (standard deviation, 
SD = 1.2 Gy) and was independent of FIGO stage as shown 
in Table 2. When EBT was combined with EBRT (n = 24), 
excluding the patient treated for recurrence, the total radiation 
dose of the two therapies combined ranged from 40 Gy to 70.4 
Gy with a mean value of 60.7 Gy (SD = 5.8 Gy). Again, the 
total dose was independent of FIGO stage for these patients 
as indicated in Table 3. EBT dose was prescribed to a depth 
of 0.5 cm from the surface of the applicator, and the upper 
third to the upper half of the vagina was treated. The most 
commonly used vaginal cylinder diameter was 30 mm from 
a range of 20 mm to 35 mm (Table 4).
Adverse events
Of 41 patients, 13 (31.7%) had adverse events. Adverse events 
were mild to moderate (Grade 1–2) in 12 of the 13 patients, 
and there was one occurrence of a Grade 3 adverse event in 
one patient. Adverse events consisted primarily of temporary 
diarrhea and dysuria, vaginal mucositis, and rectal mucosal 
irritation and discomfort. The   majority of patients (68.3%) 
experienced no gastrointestinal or genitourinary side effects. 
All adverse events are listed in Table 5, and the severity grade 
is shown if it was recorded in the   medical record.
Table 1 Patient characteristics
n (%)
Patients (n) 41 (100%)
Age range (years)
40–49 3 (7.3%)
50–59 12 (29.3%)
60–69 13 (31.7%)
70–79 10 (24.4%)
80–89 3 (7.3%)
FigO cancer stagea
IAG unspecified 1 (2.4%)
iBg1  3 (7.3% )
iBg2 4 (9.8%)
iBg3  8 (19.5%)
IBG unspecified 1 (2.4%)
icg1  2 (4.9%)
icg2 3 (7.3%)
icg3 1 (2.4%)
ICG unspecified 2 (4.9%)
iiAg1  1 (2.4%)
iiAg2 1 (2.4%)
iiAg3  1 (2.4%)
iiBg1 1 (2.4%)
iiBg2 2 (4.9%)
iiBg3 2 (4.9%)
iiiAg3 2 (4.9%)
IIIAG unspecified 1 (2.4%)
iiicg2 2 (4.9%)
iiicg3b 3 (7.3%)
Unspecified (high-grade)c 1 (2.4%)d
grading
g1 7 (17.1%)
g2 12 (29.3%)
g3 16 (39%)
G unspecified 6 (14.6%)
Time (days) from hysterectomy to first EBTe
Mean ± sD 96.2 ± 60.1
Median 80.0
range 20–255
Notes: aFederation international gynecology and Obstetrics (FigO) gynecologic 
cancer  staging  system;  bone  patient  in  this  group  was  treated  for  recurrent 
endometrial cancer; cthe “unspecified (high-grade)” cancer was a primary endometrial 
cancer; ddue to rounding, numbers do not total exactly 100%; eincludes only patients 
with primary endometrial cancer in this study.
Abbreviations: eBT, electronic brachytherapy, sD, standard deviation.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Of the 16 patients treated with EBT alone 12 (75.0%) 
were followed for more than three months and six (37.5%) 
for more than six months. There were no early adverse 
events occurring in the first three months post-treatment 
in these patients. Late adverse events first reported at least 
three months after the last EBT fraction included four adverse 
events in three patients. One patient with blood tinged stool 
(day 119) and rectal bleeding (day 210) was diagnosed 
with a superficial rectal ulcer with Grade 2 toxicity during 
colonoscopy; the last follow-up visit (day 328) indicated that 
the events were less frequent with no alteration of gastroin-
testinal function. One patient (day 125) had anal discomfort, 
which resolved completely, and discomfort with intercourse, 
which did not require intervention. One patient had Grade 
1 vaginal mucositis at day 115, and subsequent follow-up 
has not yet occurred.
The single recorded Grade 3 adverse event in the 
study was vaginal mucosa toxicity, with chronic moist 
  desquamation recorded in the medical record at day 79 
f  ollowing the last brachytherapy fraction. No further mention 
of this finding was found in this patient’s medical record at 
the next follow-up visit (day 128). At that point, the record 
did show vaginal discomfort, irritation, and occasional 
serosanguinous discharge following the use of a dilator. 
This patient was the one patient in the study with recurrent 
endometrial cancer. The primary cancer was diagnosed in 
mid-2005 with poorly differentiated Stage III endometrial 
carcinoma and treated with TAH-BSO, segmental colonic 
resection, and six cycles of chemotherapy (carboplatin and 
paclitaxel). The cancer recurred with distant metastases 
and friable exophytic vaginal lesions from the previously 
diagnosed endometrial cancer. She received an additional 
six cycles of chemotherapy (carboplatin and gemcitabine) 
prior to the study treatment, which was a combined radiation 
treatment with 55.4 Gy EBRT and 25 Gy EBT, administered 
in five fractions using a 30 mm applicator.
Discussion
This retrospective multicenter study evaluated treatment 
outcomes in patients treated with vaginal EBT as postsurgical 
adjuvant therapy for endometrial cancer. The study included 
patients with stages IA–IIIC endometrial cancer, according 
to the FIGO gynecologic staging system, and included one 
patient with recurrent Stage IIIC endometrial cancer. As a 
retrospective study, there is greater variation in the treatment 
protocols between patients than would have been treated in a 
prospective study with specific patient selection criteria and a 
treatment protocol. In this study, the prescribed dose range of 
vaginal EBT ranged from 8.0 to 30.0 Gy, and was successfully 
delivered as prescribed in all 41 patients. The treated area of 
Table 2 summary of prescription doses for patients receiving 
electronic brachytherapy only categorized by FigO stage
FIGO  
stage
Patients (n) EBT dose  
(Gy)
Fractions 
(n)
Mean total   
dose (Gy)
iA – – – –
iB 9 18–24 3,4 21.3
ic 4 21–22 3,4 21.3
iiA 2 21 3 21
iiB – – – –
iiiA 1 22 4 22
iiic – – – –
Unknown – – – –
Total 16 – – 21.3 ± 1.2
Abbreviations:  gy,  gray;  eBT,  electronic  brachytherapy;  FigO,  Federation 
international gynecology and Obstetrics.
Table 3 summary of prescription doses for patients receiving electronic brachytherapy plus external beam radiation therapy categorized 
by FigO stage
FIGO stage Patients (n = 24) EBT dose (Gy) Fractions (n) EBRT dose (Gy) Combined dose 
range (Gy)
Mean combined 
dose (Gy)
iA 1 20 4 50.4 70.4 70.4
iB 7 12–21 3,4 20–50.4  40–66 58.5
ic 4 10–18 2,3,4 45–59.4 61–69.4 64.1
iiA 1 15 3 45 60 60.0
iiB 5 12–21 3 45–46.8 57–66 60.7
iiiA 1 20 5 45 65 65.0
iiic 4 8–18 2,3 41.4–50.4 57–60 58.7
Unknown 
(high-grade)
1 12 2 44 56 56
Mean ± sDa 15.3 ± 3.7 45.4 ± 6.4 60.7 ± 5.8
recurrence iiic 1 25 5 55.4 80.4 80.4
Notes: aThe mean dose and standard deviation calculations do not include the patient with recurrent cancer. 
Abbreviations: gy, gray; eBrT, external beam radiation therapy; eBT, electronic brachytherapy; sD, standard deviation; FigO, Federation international gynecology and 
Obstetrics.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the upper third to upper half of the vagina, treatment depth, 
and selected cylinder diameters are consistent with reported 
practice patterns.16 Treatment times were not collected in this 
study, but would be expected to be consistent with the mean 
treatment time of 4.9 minutes reported by Dickler et al in 
a prospective study of 15 patients with endometrial cancer 
treated with mean EBT doses of 20.2 Gy, which is comparable 
with our mean dose of 20.0 Gy.15
No recurrences have been reported to date in these 
patients; however, the duration of follow-up is less than one 
year in nearly all patients. Numerous studies of the use of 
vaginal brachytherapy have demonstrated good control rates 
with minimal morbidity.4–13 Recently, a large multicenter 
study showed that vaginal brachytherapy treatment alone 
compared with EBRT provides a better quality of life over 
EBRT and should be the preferred treatment from a quality 
of life perspective, when appropriate, as the sole treatment 
for endometrial cancer.17
In this study, the majority of patients (28/41) had no 
adverse events, and 12 patients, who were treated for 
  primary endometrial cancer, had only low-grade adverse 
events (Grade 1 or 2) following treatment. These results 
are consistent with those reported by Dickler et al in which 
15 patients were treated with EBT alone or in combination 
with EBRT for endometrial cancer.18 In the present study, 
one patient, who was treated for a recurrence in the combined 
radiation group, exhibited a Grade 3 adverse event. Adverse 
events were numerically more common in the combined 
radiation group (36.0%) compared with the EBT alone group 
(18.8%); however, the small sample size does not warrant 
statistical testing. Interestingly, the EBT alone group had 
no acute adverse events during the first three months fol-
lowing the last fraction. The four events that occurred in 
this group were first recorded at 3.8 months post-treatment 
or later (Table 5). In contrast, 16 of 20 events that occurred 
Table 5 Adverse events by patient following treatment with electronic brachytherapy alone or in combination with external beam 
radiation therapy as recorded at follow-up visits
Patient number AEs for patients treated with EBT and EBRT  Days post EBT (n) CTC Gradea 
1-1 Diarrhea 5 1
1-2 Diarrhea  10 1
2-1 Diarrhea, fatigue 43 1, 2
3-1 erythema at introitus  14 1
3-2 Diarrhea 36 1
4-1 Dysuria, abdominal discomfort 2 1
hemorrhoid, abdominal discomfort 99 2, 1
4-2 Dysuria related to external beam therapy 14 2
Fungal skin rash related to external beam therapy 14 2
 
 
4-3
Burning/flushing sensation at tumor site related to external beam  13 2
Diarrhea related to external beam therapy  13, 111 1, 2
Dysuria  13 2
Diverticulosis, hepatomegaly related to eBT 111 1, 1
renal stone (small right) 111 nA
 
 
4-4
Dysuria (end micturition)  38, 79 nA
Bladder spasms, occasional  38, 79 nA
chronic moist desquamation of vaginal mucosa  79 3
Vaginal discomfort/irritation  38, 128 nA
serosanguinous discharge with use of dilator (occasional)  128 nA
4-5 Urgency (occasional)  85 nA
Aes for patients treated with eBT only
5-1 Blood-tinged mucous stool  119 nA
Superficial rectal ulcer with bleeding 210, 266, 328 2
6-1 Anal discomfort, discomfort with intercourse 125 nA
7-1 Vaginal mucositis 115 1
Note: aThe Ae common Terminology criteria (cTc) grade is shown if provided in the patient record.
Abbreviations: Ae, adverse event; eBT, electronic brachytherapy; eBrT, external beam radiation therapy; nA, not available.
Table 4 electronic brachytherapy treatment summary
Treated area n (%)
Upper half 26 (63)
Upper third 15 (37)
Applicator size (diameter)
20 mm 6 (14)
25 mm 8 (20)
30 mm 24 (59)
35 mm 3 (7)OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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in the combined   radiation group were recorded in the first 
three months   following the last radiation treatment.
The one patient with a Grade 3 adverse event (moist 
desquamation of vaginal mucosa) was treated for   recurrent 
disease in the form of exophytic lesions in the vagina. She had 
received chemotherapy (two courses of six cycles each) fol-
lowing TAH-BSO for primary endometrial cancer, and sub-
sequently was found to have exophytic lesions in the vagina 
and left lower pelvis recurrence in October 2008. She was 
then treated with a high total dose of 80.4 Gy with combined 
radiation therapy, of which the vaginal brachytherapy dose 
consisted of five fractions of 5 Gy each. Two factors may have 
contributed to the Grade 3 adverse event. First, the 12 cycles 
of chemotherapy might have lowered the tissue tolerance of 
the vaginal mucosa, leaving the tissue more susceptible to 
radiation effects. Second, in standard vaginal brachytherapy, 
occult cells are treated at a 5 mm depth and the normally 
intact superficial mucosa must tolerate the surface dose of 
vaginal brachytherapy. With the exophytic tumor lesions, the 
vaginal surface was damaged and not continuously intact 
while receiving the surface dose equivalent of the 5 Gy 
prescribed dose to 5 mm depth. The adverse event resolved 
completely; however, a combination of prior chemotherapy 
and superficial lesions at the contact points may predispose 
such patients to a greater risk of higher-grade adverse events. 
Dickler et al compared the dosimetry of an EBT source with 
that of a 192iridium source in patients treated for endometrial 
cancer. The results showed a higher surface dose but generally 
decreased exposure to nearby tissues with the EBT source.15  
Dosimetric results from the EBT source may offer certain 
advantages and disadvantages that must be carefully weighed 
against those of the 192iridium source for each patient. A retro-
spective study cannot provide a perspective on patient selec-
tion for the study intervention because patients who did not 
receive the treatment are by definition not part of the study. 
This study is also somewhat limited by the inconsistencies 
inherent in a multicenter study because treatment planning, 
delivery, and standards of care vary from site to site. The 
benefits of a retrospective, multicenter study lie in providing 
an observation of treatment of a broad patient population in 
a real world setting.
Conclusion
This retrospective multicenter study showed that EBT with 
vaginal cylinders is feasible and well tolerated as a postsur-
gical adjuvant radiation therapy for primary endometrial 
cancer. Additional studies are warranted to assess late toxicity 
and local control further.
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